The EU5 market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is dynamic and evolving. More than ten key branded DMTs are available, with several launching in the past five years, each delivering a unique balance of benefit, risk, and convenience. New agents, in particular oral DMTs, have meaningfully altered physician preferences and introduced new complexity into an already complicated treatment paradigm. Understanding the many decision points facing EU5 neurologists in the shifting treatment of MS provides, and in five unique countries, important context for developers of marketed and pipeline DMTs.
- Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (EU)
Author(s): John Crowley
John leads DRG’s Infectious, Niche, & Rare Diseases team and manages the market research portfolio across niche and rare diseases, anti-infectives, and vaccines. Prior to his current role, he was a Director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. John holds a Ph.D. from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute.